Abstract
Fulminant hepatitis (FH) is defined as a clinical syndrome that develops as a result of massive necrosis of liver cells followed by severe impairment of hepatic function due to viral infection or drugs, in a patient in whom there has been no previous evidence of liver disease. The mortality rate of this condition is extremely high1–3. A nationwide survey conducted in Japan comprising the period 1974–1976, when steroid hormone and/or blood exchange was believed to be useful, revealed a 16.5% survival in FH cases4.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sherlock S, Parbhoo P. The management of hepatic failure. Postgrad Med J 1971; 47: 493–498.
Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Disease, 3rd edn. New York: Grune & Stratton, 1970: 282–298.
Karvoutzis GG, Redeker AG, Peters RL. Long-term follow-up studies on patients surviving fulminant viral hepatitis. Gastroenterology 1974; 67: 870–877.
Takahashi Y, Shimizu M, Kosaka M. Nation-wide statistics of fulminant hepatitis (Jap). Saishin Igaku 1979; 34: 2285–2292.
Bucher NLR, Swaffield MN. Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon. Proc Natl Acad Sci USA 1975; 72: 1157–1160.
Starzl TE, Watanabe K, Porter KA, Putnam CW. Effects of insulin, glucagon and insulin/glucagon infusion on liver morphology and liver cell division after complete portacaval shunt in dogs. Lancet 1976; 1: 821–825.
Caruana JA, Gage AA. Increased uptake of insulin and glucagon by the liver as a signal for regeneration. Surg Gynecol Obstet 1980; 150: 390–394.
Caruana J A, Goldman JK, Camara DS, Gage AA. Insulin, glucagon and glucose in the regeneration response of the liver. Surg Gynecol Obstet 1981; 153: 726–730.
Leffert HL, Koch KS, Moran T, Rubalcava B. Hormonal control of rat liver regeneration. Gastroenterology 1979; 76: 1470–1482.
McGowan JA, Strain AJ, Bucher NLR. DNA synthesis in primary cultures of adult rat hepatocytes in a defined medium: Effect of epidermal growth factor, insulin, glucagon, and cyclic AMP. J Cell Physiol 1981; 108: 353–363.
Farivar M, Wands JR, Isselbacher KJ, Bucher NLR. Effect of insulin and glucagon on fulminant murine hepatitis. N Engl J Med 1976; 296: 1517–1519.
Okita K, Noda K, Fukumoto Y, Kodama T, Takemoto T. Protection against liver cell necrosis by synergistic action of glucagon and insulin. Acta Hepatol Japan 1978; 19: 848–853.
Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; 2: 75–80.
Berk PD, Popper H. Fulminant hepatic failure. Am J Gastroenterol 1978; 69: 349–400.
Report from the European Association for the Study of the Liver (EASL). Randomized trial of steroid therapy in acute liver failure. Gut 1979; 20: 620–623.
Takahashi Z. Annual report of nation-wide statistics of fulminant hepatitis — 1982, 1983, 1985. (Supported by a Grant-in-Aid from the Japanese Ministry of Health and Welfare.) Personal communication, 1985.
Editor information
Rights and permissions
Copyright information
© 1987 MTP Press Limited
About this chapter
Cite this chapter
Okita, K., Matsuda, S., Takemoto, T. (1987). Clinical evaluation of glucagon and insulin in therapy of fulminant hepatitis. In: Picazo, J. (eds) Glucagon in 1987. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3185-5_10
Download citation
DOI: https://doi.org/10.1007/978-94-009-3185-5_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7929-7
Online ISBN: 978-94-009-3185-5
eBook Packages: Springer Book Archive